Media

Thetford Mines, Quebec – December 12, 2024 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”), a leader in innovative technological solutions for healthcare professionals, is pleased to announce that its subsidiary, Groupe Technologique KDA (“Tech KDA”), in partnership with Pharmacie Horizon Santé and Dr. Éric Poirier, surgical oncologist practicing at the Clinique des Maladies du Sein at the Centre Hospitalier Universitaire de Québec (CHU de Québec-Université Laval), has signed a letter of intent, dated December 11, 2024, to integrate the innovative Medherize platform. This project aims to address the complex challenges associated with managing outpatient oncology treatments for breast cancer patients.

Thetford Mines, Quebec – December 3, 2024 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”), a leader in innovative technological solutions for healthcare professionals, is pleased to announce an important update regarding our progress towards certification with the Québec Health Record / Dossier Santé Québec (“DSQ”), the province-wide platform enabling the secure exchange of prescriptions, laboratory results, and imaging between healthcare professionals and patients for our project Medherize.

Thetford Mines, Quebec – November 21, 2024 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”), a leader in innovative technological solutions for healthcare professionals, is proud to announce the appointment of the Honorable Jean Charest as the Corporation’s new Strategic Advisor. This milestone marks a significant step in the strategic development of KDA as it continues its commitment to redefining the future of healthcare through digital innovation.

Thetford Mines, Quebec – August 1, 2024 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”), announces the launch of Medherize, an innovative initiative to improve the management of specialized treatments for metastatic breast cancer. Developed in collaboration with doctors, pharmacists and patients, this platform aims to enhance the quality of care and support for healthcare professionals and patients.

Thetford Mines, Quebec – June 12, 2024 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”), a leader in healthcare and medical technology innovation, is proud to announce the launch of Medherize, its revolutionary new platform dedicated to the clinical management of patients requiring specialized medications. This pioneering project particularly focuses on CDK 4/6 inhibitors used in the treatment of breast cancer, with the objective of ensuring optimal and personalized patient follow-up.